RABINOWITZ DANIEL sold $90K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 334 shares of Natera, Inc. (NTRA) at $267.99 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the specific open-market sale by the company’s Chief Legal Officer, including execution price and that it followed a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling optics, but the 10b5-1 structure makes this more of a routine disclosure than a catalyst.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, changes in guidance, or operational developments.

Relevance 2/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz, Chief Legal Officer, sold 334 shares at $267.9893 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing discloses the sale size, price, and that it was executed under a pre-arranged 10b5-1 plan, reducing the likelihood of an immediate information shock.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

10b5-1 sales can reflect routine liquidity planning rather than bearish expectations, so the market may ignore it.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Daniel Rabinowitz

    Chief Legal Officer who sold 334 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.